A C-suite executive at a small/medium women’s health pharma company has expertise in molecular biology/genetics, precision medicine, ovarian health & aging, fertility, and menopause. This stakeholder discusses precision medicine strategies for fertility and menopausal care. They consider investment, research, demonstrated clinical utility/validity, gold standard for testing, and limited access to care to be key challenges. They rate unmet needs highest in endometriosis and precision medicine activity in the next 1-2 years highest in menstrual health and fertility. They are excited by activity from Celmatix, Luca Biologics, Clue, Flow, Kindbody, Contraline, Gameto, Fertility, Inne, and WHOOP. They are also excited by companies working on menstrual blood biomarkers and smart tampons. This stakeholder discusses the current deployment of precision medicine strategies, unmet needs, complexity of disease, and future opportunity for precision medicine in menopausal care. In the future, they expect to see the most activity in fertility, menstrual health, and digital health spaces which bring technologies into the home and allow for daily monitoring to enable future research.

Campaign Details

Precision Medicine Opportunities in Women’s Health Ad Board

DeciBio conducted 11 interviews with OB/GYNs and KOLs in biotech / VC / pharma to explore key unmet needs / challenges, opportunities for precision medicine, and emerging players in women’s health.